Beam Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Beam Therapeutics Inc. (BEAM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $45.38 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $57.57, a 22.39% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $47.04, a 17.86% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $57.27, a 9.45% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $63.25, a 73.72% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $43.30, a 19.55% decline from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $53.82, a 10.57% decline from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $60.18, a 7.64% increase from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $55.91, a 48.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.38 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $57.57 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $43.30 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $43.43 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $44.06 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $47.04 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $53.82 10-K · filed 2025-02-25 | |||
| 2024-09-30 | $47.76 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $50.64 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $57.27 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $60.18 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $61.93 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $61.47 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $63.25 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $55.91 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $55.89 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $54.09 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $36.41 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $37.65 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $28.53 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $28.84 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $9.06 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $7.27 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $7.33 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $7.62 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $8.56 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |